Oshani Pieris-Steelman
Family · Edmond, OKNPI 1841711488
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,096, more than ten times the $88 reported in 2022. Among family clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$742
- AbbVie$497
- E.r. Squibb & Sons, L.L.C.$358
- Teva Pharmaceuticals USA, Inc.$336
- Alkermes, Inc.$304
- Johnson & Johnson$282
- plus $822 from 9 others
What the payments were for
- Food & beverage$3,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $742 |
| AbbVie | 44 | $497 |
| E.r. Squibb & Sons, L.L.C. | 13 | $358 |
| Teva Pharmaceuticals USA, Inc. | 17 | $336 |
| Alkermes, Inc. | 15 | $304 |
| Johnson & Johnson | 16 | $282 |
| Otsuka America Pharmaceutical, Inc. | 14 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $167 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Almatica Pharma LLC | 3 | $62 |
| Lundbeck LLC | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Corium, LLC | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$118
How this compares
$3,340 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 12 | $414 |
| Olanzapine | 16 | $334 |
| Quetiapine Fumarate | 12 | $129 |
| Trazodone Hcl | 19 | $63 |
| Fluoxetine Hcl | 28 | $37 |
| Alprazolam | 14 | $12 |
Paid to pharmacies, not to this prescriber.
Other family in Edmond
- Wendy ParksEdmond$11K
- Allison DuncanEdmond$7K
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.